YAP silencing enhanced the response to RAF and MEK inhibitor in a wide spectrum of BRAF-mutated cancer cell lines, and patients who have BRAF-mutated tumors with lower YAP expression respond better to treatment with RAF and MEK inhibitor [115, 116]. The gene discussed is YAP1; the disease is cancer.